317 related articles for article (PubMed ID: 22100373)
21. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
Huang RY; Rahman R; Ballman KV; Felten SJ; Anderson SK; Ellingson BM; Nayak L; Lee EQ; Abrey LE; Galanis E; Reardon DA; Pope WB; Cloughesy TF; Wen PY
Clin Cancer Res; 2016 Feb; 22(3):575-81. PubMed ID: 26490307
[TBL] [Abstract][Full Text] [Related]
22. Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker.
Jain R; Scarpace LM; Ellika S; Torcuator R; Schultz LR; Hearshen D; Mikkelsen T
J Neurooncol; 2010 Feb; 96(3):423-31. PubMed ID: 19859666
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
Hwang EI; Jakacki RI; Fisher MJ; Kilburn LB; Horn M; Vezina G; Rood BR; Packer RJ
Pediatr Blood Cancer; 2013 May; 60(5):776-82. PubMed ID: 22976922
[TBL] [Abstract][Full Text] [Related]
24. Diffusion-weighted imaging of local recurrent prostate cancer after radiation therapy: comparison with 22-core three-dimensional prostate mapping biopsy.
Hara T; Inoue Y; Satoh T; Ishiyama H; Sakamoto S; Woodhams R; Baba S; Hayakawa K
Magn Reson Imaging; 2012 Oct; 30(8):1091-8. PubMed ID: 22819584
[TBL] [Abstract][Full Text] [Related]
25. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
McDonald CR; Delfanti RL; Krishnan AP; Leyden KM; Hattangadi-Gluth JA; Seibert TM; Karunamuni R; Elbe P; Kuperman JM; Bartsch H; Piccioni DE; White NS; Dale AM; Farid N
Neuro Oncol; 2016 Nov; 18(11):1579-1590. PubMed ID: 27106406
[TBL] [Abstract][Full Text] [Related]
26. Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients.
Rieger J; Bähr O; Müller K; Franz K; Steinbach J; Hattingen E
J Neurooncol; 2010 Aug; 99(1):49-56. PubMed ID: 20035366
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of high b-value diffusion-weighted MRI in the diagnosis of Creutzfeldt-Jakob disease.
Riva-Amarante E; Jiménez-Huete A; Toledano R; Calero M; Alvarez-Linera J; Escribano J; Sánchez Migallón MJ; Franch O
Neurologia; 2011; 26(6):331-6. PubMed ID: 21345540
[TBL] [Abstract][Full Text] [Related]
28. Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab.
Kothari P; White NS; Farid N; Chung R; Kuperman JM; Girard HM; Shankaranarayanan A; Kesari S; McDonald CR; Dale AM
AJNR Am J Neuroradiol; 2013 Sep; 34(9):1752-1757. PubMed ID: 23578667
[TBL] [Abstract][Full Text] [Related]
29. Proton magnetic resonance spectroscopy and diffusion-weighted imaging in intracranial cystic mass lesions.
Lai PH; Hsu SS; Ding SW; Ko CW; Fu JH; Weng MJ; Yeh LR; Wu MT; Liang HL; Chen CK; Pan HB
Surg Neurol; 2007; 68 Suppl 1():S25-36. PubMed ID: 17963918
[TBL] [Abstract][Full Text] [Related]
30. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas.
Server A; Kulle B; Gadmar ØB; Josefsen R; Kumar T; Nakstad PH
Eur J Radiol; 2011 Nov; 80(2):462-70. PubMed ID: 20708868
[TBL] [Abstract][Full Text] [Related]
31. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
[TBL] [Abstract][Full Text] [Related]
32. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
[TBL] [Abstract][Full Text] [Related]
33. Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging.
McKinney AM; Kieffer SA; Paylor RT; SantaCruz KS; Kendi A; Lucato L
AJR Am J Roentgenol; 2009 Jul; 193(1):192-206. PubMed ID: 19542414
[TBL] [Abstract][Full Text] [Related]
34. Diffusion weighted imaging of pediatric and adolescent malignancies with regard to detection and delineation: initial experience.
Alibek S; Cavallaro A; Aplas A; Uder M; Staatz G
Acad Radiol; 2009 Jul; 16(7):866-71. PubMed ID: 19394872
[TBL] [Abstract][Full Text] [Related]
35. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Mrugala MM
Neurology; 2009 Feb; 72(8):773; author reply 773-4. PubMed ID: 19248218
[No Abstract] [Full Text] [Related]
36. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.
Xu PJ; Yan FH; Wang JH; Shan Y; Ji Y; Chen CZ
J Comput Assist Tomogr; 2010 Jul; 34(4):506-12. PubMed ID: 20657216
[TBL] [Abstract][Full Text] [Related]
37. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Narita Y
Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
[TBL] [Abstract][Full Text] [Related]
38. Added value of diffusion-weighted imaging in the MRI assessment of perilesional tumor recurrence after chemoembolization of hepatocellular carcinomas.
Yu JS; Kim JH; Chung JJ; Kim KW
J Magn Reson Imaging; 2009 Jul; 30(1):153-60. PubMed ID: 19557734
[TBL] [Abstract][Full Text] [Related]
39. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma.
Gu J; Chan T; Zhang J; Leung AY; Kwong YL; Khong PL
AJR Am J Roentgenol; 2011 Sep; 197(3):W384-91. PubMed ID: 21862763
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.
Hofer S; Elandt K; Greil R; Hottinger AF; Huber U; Lemke D; Marosi C; Ochsenbein A; Pichler J; Roelcke U; Weder P; Zander T; Wick W; Weller M
Acta Oncol; 2011 Jun; 50(5):630-5. PubMed ID: 21495907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
